

**Have you ever
had a heart
attack or stroke?**

**Do you have
poor circulation?**



Have you considered participating in a clinical study?

Participating in this clinical study has the potential to improve future treatment options for people living with cardiovascular disease.

What is the REDEFINE 3 study?

REDEFINE 3 is looking at the combination of cagrilinitide and semaglutide (CagriSema), which has the potential to impact cardiovascular risk factors. REDEFINE 3 is needed to help us understand the safety and potential benefits of CagriSema on the cardiovascular system.

What are the BENEFITS for you?

- Expert medical care and education from a dedicated team of doctors and nurses
- Study-related care, including regular health check-ups
- Helping others by contributing to medical research

You may qualify to participate if:

- You have had a stroke, a heart attack (myocardial infarction), or have poor circulation (peripheral arterial disease)
- You are 55 years of age or older
- You are living with overweight or obesity (BMI \geq 25 kg/m²)
- You must have type 2 diabetes and/or chronic kidney disease
- You are able to attend regular clinic visits and receive phone calls over a period of 2,5 – 4,5 years, depending on when you start with the study



This study is currently recruiting – please contact:
Providence Health Partners-Center for Clinical Research

Lisa Todd, Study Coordinator
(937) 297-8999
research@provmedgroup.com

REDEFINE 3

cagrilinitide and
semaglutide
combination | assessing
cardiovascular
outcomes and safety

Trial-ID: NN9838-4942
US & CA English Master, Version 2.0,
Date: 01-Nov-2023

